This surge is driven by India’s strong position in Active Pharmaceutical ingredients (API) and generic drug manufacturing, along with cost advantages over China.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Leave a Comment